title: Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center.
abstract: More than 1,100 transplants have been performed at WFUBMC, including 60 pediatric transplants and 40 pancreas transplants. The one-year living donor kidney graft survival rate exceeds 90% and the 2 year deceased donor kidney graft survival rate exceeds 80%. The current active waiting list includes more than 300 candidates. Despite more transplants being performed, we continue to under-serve our referral area, which has among the highest rates of hypertension, diabetes, and end stage renal disease in the country. The AOTP has experienced a period of rapid growth over the past 2 years based upon sharing of zero HLA antigen-mismatched kidneys, use of ECD kidneys, liberalization of donor and recipient selection criteria, and the continued development of the pancreas transplant and laparoscopic donor nephrectomy programs. The pancreas transplant program will continue to grow as the waiting list enlarges and matures, with a 200% increase in activity expected within the next few years. The LDKT program will expand as more emphasis is placed on our pretransplant practice, including the more liberal application of laparoscopic donor nephrectomy, which has now become a standard procedure at our WFUBMC is involved in a number of clinical research projects studying new immunosuppressive agents and regimens. In this chapter, we have presented our recent experience with KTX in the elderly, ECD kidneys, alternate day Thymoglobulin administration, valganciclovir prophylaxis, SRL conversion using daclizumab bridge therapy, and pancreas transplantation with portal-enteric drainage. We plan to initiate a number of new protocols in the immediate future, including desensitization of the highly sensitized patient, ABO incompatible transplantation, transplantation of the HIV-positive patient, steroid withdrawal and avoidance regimens, living kidney donation from the anonymous altruistic donor, paired kidney exchanges from living donors, and islet transplantation. WFUBMC remains the most active donor hospital in North Carolina, and a non-heart beating donor protocol has been successfully initiated at our facility. Although much has been accomplished, a number of challenges remain. We look forward to building on our accomplishments, confronting the challenges, and achieving a level of excellence that could only be attained by mutual commitment from a dedicated, multidisciplinary team.
authors.affiliation: Department of General Surgery, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Stratta
authors.forename: Michael S
authors.initials: MS
authors.lastname: Rohr
authors.forename: Patricia L
authors.initials: PL
authors.lastname: Adams
authors.forename: Aimee K
authors.initials: AK
authors.lastname: Sundberg
authors.forename: Erica L
authors.initials: EL
authors.lastname: Hartmann
authors.forename: Greg
authors.initials: G
authors.lastname: Armstrong
authors.forename: Teresa K
authors.initials: TK
authors.lastname: Anderson
authors.forename: Alan C
authors.initials: AC
authors.lastname: Farney
authors.forename: Julie A
authors.initials: JA
authors.lastname: Roskopf
authors.forename: Gloria
authors.initials: G
authors.lastname: Hairston
authors.forename: David F
authors.initials: DF
authors.lastname: Kiger
authors.forename: Shashi K
authors.initials: SK
authors.lastname: Nagaraj
authors.forename: Samy S
authors.initials: SS
authors.lastname: Iskandar
authors.forename: Dean G
authors.initials: DG
authors.lastname: Assimos
mesh_terms: D000046:Academic Medical Centers; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D000077561:Daclizumab; D004334:Drug Administration Schedule; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D009657:North Carolina; D016035:Pancreas Transplantation; D020123:Sirolimus / Q000627:therapeutic use; D014019:Tissue Donors; D009927:Tissue and Organ Procurement / Q000379:methods; D000077562:Valganciclovir
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D000998:Antiviral Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D000077562:Valganciclovir; D015774:Ganciclovir; D020123:Sirolimus